Related Experiment Video
Updated: May 4, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
15.4K
Statin improves flow-mediated vasodilation in chronic kidney diseases
Tsuneo Takenaka1, Hiroshi Takane2, Tomohiro Kikuta2
1International University of Health and Welfare, Clinical Research Center, Sanno Hospital, 8-10-16 Akasaka, Minato, Tokyo 107-0052, Japan ; Saitama Medical University, Department of Nephrology, 36 Morohongo, Moroyama, Iruma, Saitama 350-0495, Japan.
International Journal of Hypertension
|January 8, 2014
Summary
Combining amlodipine and atorvastatin in a single pill improved medication adherence and lipid profiles in chronic kidney disease (CKD) patients. This combination also enhanced flow-mediated dilation (FMD) and reduced proteinuria, suggesting improved endothelial function.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Managing chronic kidney disease (CKD) often requires multiple medications.
- Poor drug adherence is a significant challenge in CKD patient populations.
- Hypertension and dyslipidemia are common comorbidities in CKD.
Purpose of the Study:
- To evaluate the impact of a fixed-dose combination drug (amlodipine and atorvastatin) on adherence and clinical outcomes in CKD patients.
- To assess the effects of the combination drug on lipid profiles, flow-mediated dilation (FMD), and proteinuria.
- To investigate the relationship between proteinuria and FMD in CKD patients.
Main Methods:
- A 6-month observational study involving 36 CKD patients with hypertension and dyslipidemia.
- Patients were switched from separate amlodipine (5 mg) and atorvastatin (10 mg) pills to a combination drug with equivalent doses.
- Measurements included lipid profiles, FMD, proteinuria, and high-sensitivity C-reactive protein (hs-CRP).
Main Results:
- The combination drug significantly improved lipid profiles, decreasing total cholesterol and triglycerides while increasing HDL cholesterol.
- Flow-mediated dilation (FMD) showed a significant improvement from 2.4% to 2.7%.
- Subanalysis revealed that the combination drug reduced proteinuria and hs-CRP in patients with significant cholesterol reduction.
Conclusions:
- Proteinuria is a key factor contributing to reduced FMD in CKD patients.
- The fixed-dose combination drug improves medication adherence and positively impacts lipid profiles and endothelial function (FMD).
- Atorvastatin in the combination drug appears to refine endothelial function and lipid profiles in CKD patients.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
679
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
679
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
559
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
559
01:22Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
01:24Chronic Kidney Disease II: Clinical Manifestations
1.1K
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:22Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa
915
The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a...
The pKa of a...
915